RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

RPG Active Pharma’s agreement to acquire the API and intermediates business of Raghava Life Sciences for up to Rs 135 crore is not, by pharmaceutical M&A standards, a mega-deal.

But it is strategically revealing.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Free Membership Required

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian Pharma 2026: The Growth Engine Is Changing

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

The paradox of the “Pharmacy of the World.” 💊

The Innovator’s Gene and the Generic’s Promise

Topics

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian Pharma 2026: The Growth Engine Is Changing

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

The paradox of the “Pharmacy of the World.” 💊

The Innovator’s Gene and the Generic’s Promise

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Anuj Pasrija Elevated to Country Lead, J&J MedTech India and Vice President – Surgery

China’s Biopharma Strategy: A Warning and Opportunity for India

Related Articles

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Company

Headlines

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian Pharma 2026: The Growth Engine Is Changing

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

The paradox of the “Pharmacy of the World.” 💊

Newsletter